Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: MG-98, MethylGene.

Z Zhang1

  • 1EPIX Medical Inc, Cambridge, MA 02142-1118, USA. zzhang@epixmed.com

Current Opinion in Molecular Therapeutics
|January 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microphthalmia (mi) in murine mast cells: regulation of its stimuli-mediated expression on the translational level.

Blood·1997
Same author

Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation.

International journal of cancer·1997
Same author

The effect of patient characteristics on response to focal laser treatment for diabetic macular edema.

Ophthalmology·1997
Same author

Use of buccal smears for rapid detection of peroxisomes.

European journal of pediatrics·1997
Same author

Development of a novel thiol reagent for probing ion channel structure: studies in a model system.

Biochemistry·1997
Same author

Fast measurements of transmission of erythema effective irradiance through clothing fabrics.

Health physics·1997
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

MG-98, an antisense oligonucleotide targeting DNA methyltransferase, is being developed for solid tumors. Phase II trials in head and neck and renal cell cancers are underway, with data anticipated in early 2002.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • DNA methyltransferase (DNMT) plays a crucial role in cancer development.
  • Antisense oligonucleotides offer a targeted approach to inhibit gene expression.

Purpose of the Study:

  • To evaluate the efficacy and safety of MG-98, a second-generation antisense oligonucleotide, in treating solid tumors.
  • To investigate the potential of MG-98 in restoring normal cellular mechanisms to combat cancer growth.

Main Methods:

  • Phase II clinical trials initiated for recurrent/metastatic squamous cell cancer of the head and neck and advanced/metastatic renal cell carcinoma.
  • MG-98 is designed to inhibit messenger RNA (mRNA) produced by the DNA methyltransferase gene.

Main Results:

Related Experiment Videos

  • Phase II data for MG-98 in solid tumors were expected in the first half of 2002.
  • Patents have been granted for DNA methyltransferase inhibition using agents like MG-98.

Conclusions:

  • MG-98 shows promise as a targeted therapy for solid tumors by inhibiting DNA methyltransferase.
  • Further clinical data are needed to confirm the efficacy and therapeutic potential of MG-98.